KAN-101 Dose 5

KAN-101 is an investigational biologic therapy being developed for the treatment of celiac disease. It is designed to induce immune tolerance to gluten by targeting specific immune pathways involved in the pathogenesis of celiac disease. The drug is administered intravenously and aims to modulate the immune response, potentially reducing or eliminating gluten-induced inflammation in patients with celiac disease who are on a gluten-free diet. Group 4 in Part B and Part C refers specifically to participants receiving "Dose 5" of KAN-101 as part of a multi-part clinical trial evaluating safety, tolerability, pharmacodynamics, and pharmacokinetics[6][8][10].